Neurochemical Research

, Volume 21, Issue 6, pp 649–652 | Cite as

Nefiracetam (DM-9384) reverses apomorphine-induced amnesia of a passive avoidance response: Delayed emergence of the memory retention effects

  • E. Doyle
  • K. M. O’Boyle
  • T. Shiotani
  • C. M. Regan
Original Articles


Nefiracetam is a novel pyrrolidone derivative which attenuates scopolamine-induced learning and post-training consolidation deficits. Given that apomorphine inhibits passive avoidance retention when given during training or in a defined 10–12h post-training period, we evaluated the ability of nefiracetam to attenuate amnesia induced by dopaminergic agonism. A step-down passive avoidance paradigm was employed and nefiracetam (3 mg/kg) and apomorphine (0.5 mg/kg) were given alone or in combination during training and at the 10–12h post-training period of consolidation. Co-administration of nefiracetam and apomorphine during training or 10h thereafter produced no significant anti-amnesic effect. However, administration of nefiracetam during training completely reversed the amnesia induced by apomorphine at the 10h post-training time and the converse was also true. These effects were not mediated by a dopaminergic mechanism as nefiracetam, at millimolar concentrations, failed to displace either [3H]SCH 23390 or [3H]spiperone binding from D1 or D2 dopamine receptor subtypes, respectively. It is suggested that nefiracetam augments molecular processes in the early stages of events which ultimately lead to consolidation of memory.

Key words

Nootropic memory consolidation dopamine D1-receptor 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Nabeshima, T. 1994. Ameliorating effects of nefiracetam (DM-9384) on brain dysfunction. Drugs of Today, 30:357–379.Google Scholar
  2. 2.
    Woodruff-Pak, D. S., and Li, Y.-T., 1994. Nefiracetam (DM-9384): Effect on eyeblink classical conditioning in older rabbits. Psychopharmacol. 114:200–208.CrossRefGoogle Scholar
  3. 3.
    Yoshii, M., and Watabe, S. 1994. Enhancement of neuronal calcium channel currents by the nootropic agent, nefiracetam (DM-9384) in NG108-15 cells. Brain Res. 642:123–131.PubMedCrossRefGoogle Scholar
  4. 4.
    Mondadori, C., Hengerer, B., Ducret, T., and Borkowski, J. 1994. Delayed emergence of effects of memory enhancing drugs: Implications for the dynamics of long-term memory. Proc. Natl. Acad. Sci. USA 91:2041–2045.PubMedCrossRefGoogle Scholar
  5. 5.
    Doyle, E., and Regan, C. M. 1993 Cholinergic and dopaminergic agents which inhibit a passive avoidance response attenuate paradigm-specific increases in NCAM sialylation state. J. Neural Transm. 92:33–49.CrossRefGoogle Scholar
  6. 6.
    Doyle, E., Regan, C. M., and Shiotani, T. 1993. Nefiracetam (DM-9384) preserves hippocampal neural cell adhesion molecule-mediated memory consolidation processes during scopolamine disruption of passive avoidance training in the rat. J. Neurochem. 61:266–272.PubMedCrossRefGoogle Scholar
  7. 7.
    Waddington, J. L., and O’Boyle, K. M. 1989. Drugs acting on brain dopamine receptors: a conceptual re-evaluation five years after the first selective D-1 antagonist. Pharmacol. Ther. 43:1–52.PubMedCrossRefGoogle Scholar
  8. 8.
    O’Boyle, K. M., and Waddington, J. L. 1992. Agonist and antagonist interactions with D1 dopamine receptors: Agonist-induced masking of D1 receptors depends on intrinsic activity. Neuropharmacol. 31:177–183.CrossRefGoogle Scholar
  9. 9.
    Squire, L., and Davis, H. P. 1981. The pharmacology of memory: A neurobiological perspective. Annu. Rev. Pharmacol. Toxicol. 21:323–356.PubMedCrossRefGoogle Scholar
  10. 10.
    McGaugh, J. L. 1989. Involvement of hormonal and neuromodulatory systems in the regulation of memory storage. Annu. Rev. Neurosci. 12:255–289.PubMedCrossRefGoogle Scholar
  11. 11.
    Ichihara, K., Nabeshima, T., and Kameyama T. 1988. Effects of haloperidol, sulpiride and SCH 23390 on passive avoidance learning in mice. Eur. J. Pharmacol. 151:435–442.PubMedCrossRefGoogle Scholar
  12. 12.
    Ichihara, K., Nabeshima, T., and Kameyama T. 1988. Opposite effects induced by low and high doses of apomorphine on singletrial passive avoidance learning in mice. Pharmacol. Biochem. Behav. 30:107–113.PubMedCrossRefGoogle Scholar
  13. 13.
    Ichihara, K., Nabeshima, T., and Kameyama, T. 1989. Differential effects of pimozide and SCH 23390 on acquisition of learning in mice. Eur. J. Pharmacol. 164:189–195.PubMedCrossRefGoogle Scholar
  14. 14.
    Castellano, C., Battaglia, M., and Sansome, M. 1992. Oxiracetam prevents haloperidol-induced passive avoidance impairment in mice. Pharmacol. Biochem. Behav. 42:797–801.PubMedCrossRefGoogle Scholar
  15. 15.
    Abe, E., Murai, S., Saito, H., Masuda, Y., Takasu, Y., Shiotani, T., Tachizawa, H., and Itoh, T. 1994. Effects of nefiracetam on deficits in active avoidance response and hippocampal cholinergic and monoaminergic dysfunctions induced by AF64A in mice. J. Neural Transm. 95:179–193.CrossRefGoogle Scholar
  16. 16.
    Bailey, C. H., and Kandel, E. R. 1993. Structural changes accompanying memory storage. Annu. Rev. Physiol. 55:397–426.PubMedCrossRefGoogle Scholar
  17. 17.
    Doyle, E., Nolan, P. M., Bell, R., and Regan, C. M. 1992. Intraventricular infusions of anti-neural cell adhesion molecules in a discrete posttraining period impair consolidation of a passive avoidance response in the rat. J. Neurochem. 59:1570–1573.PubMedCrossRefGoogle Scholar
  18. 18.
    Doyle, E., Nolan, P., Bell, R., and Regan, C. M. 1992. Hippocampal NCAM180 transiently increases sialylation during the acquisition and consolidation of a passive response in the adult rat. J. Neurosci. Res. 31:513–523.PubMedCrossRefGoogle Scholar
  19. 19.
    Odumeru, O., Murphy, K. J., Regan, C. M. and Shiotani, T. 1995. Influence of nefiracetam on NGF-induced neuritogenesis and neural cell adhesion molecule polysialic acid expression: In vivo and in vitro comparisons. Behav. Brain Res. In Press.Google Scholar

Copyright information

© Plenum Publishing Corporation 1996

Authors and Affiliations

  • E. Doyle
    • 1
  • K. M. O’Boyle
    • 1
  • T. Shiotani
    • 2
  • C. M. Regan
    • 1
  1. 1.Department of PharmacologyUniversity CollegeDublinIreland
  2. 2.Medical Development DepartmentDaiichi Pharmaceutical Co. Ltd.TokyoJapan

Personalised recommendations